Research chemicalEntactogenSerotonin releaserBenzodioxole

MBDB

Also known as Methyl-J · Eden · N-methyl-benzodioxolylbutanamine

Written by enwyReviewed 5 Aug 20261 sources0 comments

MBDB (N-methyl-1,3-benzodioxolylbutanamine) is a homolog of MDMA studied by David Nichols as a prototypical "pure" entactogen with minimal stimulant or psychedelic character. It is more selective for serotonin release, producing emotional openness with little euphoria or energy, at the cost of feeling comparatively bland to recreational users.

01 Overview

MBDB was designed to probe the entactogen concept, separating MDMA's empathogenic core from its stimulant and hedonic components. It reliably produces gentle emotional relaxation but is often described as underwhelming recreationally, which limited its street uptake.

Human data are minimal beyond early exploratory studies. Its serotonin-selective profile still carries theoretical neurotoxicity and serotonin-syndrome risk. It is controlled or falls under analog provisions in most countries.

02 Mechanism

Relatively selective serotonin-releasing agent at the serotonin transporter with weak dopamine activity, yielding entactogenic effects with little stimulation.

03 Dosing

Tier	Dose	Route	Notes
Light	100–150 mg	Oral	Threshold-to-light
Common	150–250 mg	Oral	Less potent than MDMA by weight

04 Effects

Effect	Magnitude	Evidence
Emotional relaxationGentle openness and calm without strong euphoria.	Mild-moderate	Anecdotal
Low stimulationLittle of MDMA's energy or drive, sometimes described as flat.	Minimal	Anecdotal

05 Side effects

Effect	Severity	Frequency	Evidence
Serotonergic neurotoxicitySerotonin-releasing entactogens carry theoretical axonal neurotoxicity as seen with MDMA.	Severe	Theoretical, uncharacterised in humans	Preclinical
Serotonin syndromeExcess serotonergic signalling can cause agitation, clonus, and hyperthermia.	Life-threatening	Rare, elevated with serotonergic drugs	Observational
Bruxism and insomniaJaw clenching and difficulty sleeping, as with other serotonin releasers.	Mild	Common	Anecdotal

06 Legal status

United States

Schedule I (as MDMA analog)

as of Jan 2026

United Kingdom

Class A (Misuse of Drugs Act)

as of Jan 2026

07 References

Nichols DE. Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogensJournal of Psychoactive Drugs, 1986

08 Discussion0 comments

Create account

Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.

This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.